# Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution

> **NCT00776555** · PHASE1 · TERMINATED · sponsor: **Shire** · enrollment: 3 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Lisdexamfetamine Dimesylate
- **DRUG:** Racemic mixture of dextroamphetamine and lisdexamfetamine

## Key facts

- **NCT ID:** NCT00776555
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11-21
- **Primary completion:** 2009-03-31
- **Final completion:** 2009-03-31
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was stopped by the sponsor based on a non-safety related business priority decision.
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00776555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00776555, "Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00776555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*